ArcticZymes Technologies (AZT)

[OLAV2]

Ja jeg tror, at bare de klarer og overbevise markedet om at de kan vise til vedvarende og stabil vekst. Så kan denne gå sky high igjen . Men det må bevises, før det virkelig tar av tror jeg . Men alt virker og være lagt til rette for eksponensiell vekst så det er bare å lene seg tilbake, og håpe at det går den veien vi har ventet på en stund nå

[Savepig]

Holy bounce batman

[tooeasy891]

Mr P (@tradewithmrp.substack.com)

[Staylong]

OBX eller Oxford Biomedica er på Advanced Therapies Congress i London. En av posterene de viser frem er den hvor SAN og M-SAN fremheves for bedre kvalitet i sluttproduktet i produksjon av virale vektorer.

Advanced-Nuclease-Applications-in-Lentiviral-Vector-Bioprocessing-for-Superior-Downstream-Recovery-and-Vector-Product-Quality.pdf

[tooeasy891]

AZT er der og, busy Mars

https://www.arcticzymes.com/events

[tooeasy891]

Kan virke som at OEM audit pågår nå… Nucleases for a step change in AAV /lenti / vaccine yield. Plus Norway… | Sharon Brownlow

[tooeasy891]

OXB med fy24 rapport i dag: Preliminary results for the year ended 31 December 2024 - OXB
bra presentasjon med mye bra info om markedet:
https://oxb.com/wp-content/uploads/2025/04/OXB-FY24-Preliminary-Financial-Results-09-April-2025-FINAL.pdf

[Staylong]

Bra plukket opp. Takk for deling.

[tooeasy891]

“Approval is 2,5 times higher in gene therapy than others in ph1” hørte jeg på presentasjonen, fint med 223 forskjellige bioproccesing kunder da:)

[TekBot]

Financial calendar

Financial calendar for ArcticZymes Technologies ASA

FINANCIAL YEAR 2025
…

Vis børsmeldingen

14.08.2025 - Half-yearly Report
30.04.2025 - Annual Report
27.05.2025 - Annual General Meeting

08.05.2025 - Quarterly Report - Q1
06.11.2025 - Quarterly Report - Q3

The financial calendar as previously advised by the Company is amended by a change of the date for publication of Annural Report

This information is published pursuant to the requirements set out in the Continuing obligations.

Kilde

[TekBot]

ArcticZymes Technologies ASA - Annual Report and ESG report for 2024

(Tromsø, 30 April 2025) ArcticZymes Technologies ASA (OSE:“AZT”) has published
its Annual Report together with its updated ESG report for 2024.

…

Vis børsmeldingen

Thee Annual Report and the ESG Report for 2024 is attached to this stock
exchange notice and published on www.arcticzymes.com.

The report is also published in European Single Electronic Format (ESEF) (zip
file).

This stock exchange notice is subject to the disclosure requirements in Section
5-12 of the Norwegian Securities Trading Act. This stock exchange release was
published by Børge Sørvoll, CFO on 30 April 2025 at 18.00 CET.

For additional information, please contact:
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoll@arcticzymes.com

Kilde

[Staylong]

En sånn liten sak som dette gir meg som aksjonær mer tillit til selskapet, selskapets styre og CEO. Det er sånn det skal være og man blir belønnet når prestasjonene i løpet av året tilsier det. Jeg tipper over 90% av selskapene på Oslo børs ville betalt ut noe bonus på oppnåelse av noen av KPIene som skulle utløse bonus.

Some of targets were fully completed whereas the other targets were only partially met. Due to lower-than-expected sales and EBITDA per end of the year, it was decided by the Board of Directors together with CEO that no bonus should be awarded to executive management.

[TekBot]

ArcticZymes Technologies ASA: Invitation to presentation of Q1 2025 results

The Company will host a virtual Q1 2025 presentation for investors, analysts and
media at 08:30 CET on Thursday, 8 May, 2025.

…

Vis børsmeldingen

The presentation will be given by CEO, Michael Akoh, VP Sales, Paul Blackburn
and CFO, Børge Sørvoll.

The presentation can be followed as a live webcast from Hegnar TV
on https://channel.royalcast.com/landingpage/hegnarmedia/20250508_9/ or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.

The report for Q1 2025 will be available on www.newsweb.no and on the company’s
homepage www.arcticzymes.com from 07.00 CET on Thursday, 8 May, 2025.

For further information, please contact:
CFO
Børge Sørvoll
borge.sorvoll@arcticzymes.com
+47 952 90187

Kilde

[TekBot]

ArcticZymes Technologies ASA: Notice of Annual General Meeting

The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held
on Tuesday 27. May 2025 at 12.00 CET. The meeting will be held as a physical
meeting, with an option for shareholders to participate digitally.
…

Vis børsmeldingen

Please find the notice including agenda for the meeting and appendices attached
to this disclosure. The notice and appendices will also be made available on the
Company’s homepage www.arcticzymes.com.

Shareholders who wish to attend the AGM, in person, electronically or by proxy,
are requested to complete the registration form by Friday 23. May 2025 at 13.00
CET.

This information is subject to disclosure requirements pursuant to §5-12 of the
Norwegian Securities Trading Act.

For further information, please contact:
Børge Sørvoll
CFO
+47 95 29 01 87
borge.sorvoll@arcticzymes.com

Kilde

[TekBot]

ArcticZymes Technologies announces Q1 2025 Financial results. Record Customer Base Growth Lays Foundation for Long-Term Expansion

Tromsø, Norway, May 8th, 2025 - ArcticZymes Technologies (OSE: AZT) today
announced its financial results for the first quarter of 2025, reporting total
revenues of NOK 24.9 million and an EBITDA of NOK -3.7 million. While revenues
…

Vis børsmeldingen

declined year-on-year due to a temporary reduction in orders from a major OEM
customer, the Company achieved an all-time high in customer numbers and order
volumes-highlighting early progress in its commercial transformation strategy.

Highlights:

· Total revenue for Q1 2025 was NOK 24.9 million, compared to NOK 30.0 million
in Q1 2024.
· Sales revenue amounted to NOK 23.3 million, primarily affected by a NOK 9
million decline in orders from a major OEM customer in the Molecular Tools
segment compared to Q1 2024. Excluding this customer, sales grew by 12% year-on
-year.
· EBITDA was NOK -3.7 million, compared to NOK 2.3 million in Q1 2024,
reflecting amongst others ongoing investments in commercial transformation, IT
systems, and foreign exchange effects.
· Record order activity, with a total of 342 customer orders in Q1 2025, up
from 301 in the same period last year. Orders were split between
Biomanufacturing (205) and Molecular Tools (140), with some orders containing
products from both portfolios.
· The number of Biomanufacturing orders increased by 25%, while Molecular
Tools orders rose by 3.7%, compared to Q1 2024.
· Biomanufacturing momentum continues, with 107 biomanufacturing customers in
Q1 and 227 unique customers over the past 12 months-both all-time highs.
· U.S. market acceleration, with a 25% year on year sales increase, driven by
increased activity in the cell and gene therapy (CGT) segment, particularly on
the East Coast.
· Strategic adoption of SAN HQ enzymes by a new U.S.-based CDMO for AAV
manufacturing, with an additional CDMO currently evaluating M-SAN for
integration in the second half of 2025

Commercial transformation strategy laying the groundwork for long-Term growth

ArcticZymes’ commercial transformation continues to gain traction. A growing and
increasingly diversified customer base, particularly within biomanufacturing, is
laying the foundation for long-term growth. The Company’s strategy of engaging
customers early in their process development is proving effective, especially as
enzyme adoption during the early stages of platform design tends to result in
long-term integration and recurring business. CDMOs, therapeutic and diagnostic
developers standardizing AZT enzymes in their manufacturing workflows represent
a key growth lever.

“There are early signs that our transformation efforts are beginning to pay off.
In Q1, we achieved an all-time high of 227 unique biomanufacturing customers
over the past year, with 107 in the first quarter alone. We also saw a 21% year
-on-year increase in biomanufacturing sales. The total number of customer orders
reached 342-our highest ever-and we saw strong growth in Biomanufacturing.
Importantly, a new CDMO partner in the U.S. has standardized SAN HQ in their AAV
manufacturing protocols, opening exciting long-term opportunities. These
milestones confirm the growing market traction of our offering and position us
well for sustainable growth.” Commented Michael Akoh, CEO of ArcticZymes
Technologies.

-Ends-

Presentation and Webcast
The Company will host a virtual Q1 2025 presentation for investors, analysts and
media at 8:30 CET on Thursday, May 8, 2025.

The presentation will be given by CEO, Michael Akoh, VP Sales and Marketing Paul
Blackburn and CFO, Børge Sørvoll.

The presentation can be followed as a live webcast from Hegnar TV on
https://channel.royalcast.com/landingpage/hegnarmedia/20250508_9/ or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.

The report for Q1 2025 will be available on www.newsweb.no and on the company’s
homepage www.arcticzymes.com from 07.00 CET on Thursday, May 8, 2025.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies’ IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

Kilde

[tooeasy891]

Tanker fra Labull:

@labulll.bsky.social

[TekBot]

ArcticZymes Technologies AS - Mandatory notification of trade

(Tromsø 14. May 2025) VP Operations, Marit Sjo Lorentzen has today exercised
15.000 options with a strike of NOK 10.19 per share.

…

Vis børsmeldingen

The exercise will be settled in cash through a payment from the Company, equal
to the net value of the options. Net proceeds after tax will be used to acquire
shares in the Company.

This information is subject to the disclosure requirements in the EU Market
Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:

Børge Sørvoll
CFO
952 90187
ir@arcticzymes.com

Kilde

[TekBot]

ArcticZymes Technologies ASA - flagging av fullmakter

David Zetterlund har idag mottatt fullmakter uten stemmeinstruks for å
representere inntil 1.595.000 aksjer på den ordinære generalforsamlingen 27 mai
2025. I tillegg innehar David Zetterlund 2.280.000 egne aksjer. Tilsammen
…

Vis børsmeldingen

representerer han 7,59% av aksjene i selskapet på denne generalforsamlingen.

For ytterligere informasjon:
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoll@arcticzymes.com

Kilde

[TekBot]

ArcticZymes Technologies ASA - flagging av fullmakter

Styrets leder, Frank Mathias har idag mottatt fullmakter uten stemmeinstruks for
å representere inntil 4.938.217 aksjer på den ordinære generalforsamlingen 27
mai 2025. I tillegg har han mottatt fullmakt med stemmeinstruks for inntil
…

Vis børsmeldingen

250.000 aksjer. Tilsammen representerer disse fullmaktene 10,16% av aksjene i
selskapet på denne generalforsamlingen.

For ytterligere informasjon:
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoll@arcticzymes.com

Kilde

[TekBot]

ArcticZymes Technologies ASA - Minutes form Annual General Meeting 2025

(Tromsø 27. May 2025) The Annual General Meeting of ArcticZymes Technologies ASA
(OSE:AZT) was held today, 27. May 2025 as a physical meeting with opportunity
for virtual participation.
…

Vis børsmeldingen

Attached to this announcement are the minutes of the Annual General
Meeting in Norwegian and an English translation.

All items on the agenda were adopted as proposed.

For further information, please contact:
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoll@arcticzymes.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde